Promoted Content

Promoted Content

X

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Saillant Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Netherlands

Post An Enquiry

CPhI North America Online

Participation Not Confirmed

Update your events

Saillant Therapeutics Reports Proof of Concept of its Treatment in Heart Failure showing Functional Reversal and Myocardial Rejuvenation

Contact the Supplier

Lead Product(s): ST02

Therapeutic Area: Cardiology/Vascular Diseases Product Name: ST02

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 04, 2020

Details:

Using a heart failure animal model, Saillant found out that the new treatment (ST02) restored heart function in failing hearts after four weeks of treatment. Treated hearts reversed to normal geometry with a significant reduction in scar tissue (fibrosis).